↓ Skip to main content

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

Overview of attention for article published in Frontiers in Microbiology, January 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
1 X user
patent
28 patents

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
Published in
Frontiers in Microbiology, January 2011
DOI 10.3389/fmicb.2011.00244
Pubmed ID
Authors

Sushrusha Nayak, Debalina Sarkar, George Q. Perrin, Babak Moghimi, Brad E. Hoffman, Shangzhen Zhou, Barry J. Byrne, Roland W. Herzog

Abstract

Intramuscular (IM) administration of an adeno-associated viral (AAV) vector represents a simple and safe method of gene transfer for treatment of the X-linked bleeding disorder hemophilia B (factor IX, F.IX, deficiency). However, the approach is hampered by an increased risk of immune responses against F.IX. Previously, we demonstrated that the drug cocktail of immune suppressants rapamycin, IL-10, and a specific peptide (encoding a dominant CD4(+) T cell epitope) caused an induction of regulatory T cells (Treg) with a concomitant apoptosis of antigen-specific effector T cells (Nayak et al., 2009). This protocol was effective in preventing inhibitory antibody formation against human F.IX (hF.IX) in muscle gene transfer to C3H/HeJ hemophilia B mice (with targeted F9 gene deletion). Here, we show that this protocol can also be used to reverse inhibitor formation. IM injection of AAV1-hF.IX vector resulted in inhibitors of on average 8-10 BU within 1 month. Subsequent treatment with the tolerogenic cocktail accomplished a rapid reduction of hF.IX-specific antibodies to <2 BU, which lasted for >4.5 months. Systemic hF.IX expression increased from undetectable to >200 ng/ml, and coagulation times improved. In addition, we developed an alternative prophylactic protocol against inhibitor formation that did not require knowledge of T cell epitopes, consisting of daily oral administration of rapamycin for 1-month combined with frequent, low-dose intravenous injection of hF.IX protein. Experiments in T cell receptor transgenic mice showed that the route and dosing schedule of drug administration substantially affected Treg induction. When combined with intravenous antigen administration, oral delivery of rapamycin had to be performed daily in order to induce Treg, which were suppressive and phenotypically comparable to natural Treg.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 2%
Unknown 44 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 9 20%
Researcher 6 13%
Student > Master 6 13%
Other 3 7%
Student > Ph. D. Student 3 7%
Other 10 22%
Unknown 8 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 11 24%
Medicine and Dentistry 9 20%
Biochemistry, Genetics and Molecular Biology 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Neuroscience 2 4%
Other 5 11%
Unknown 10 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2023.
All research outputs
#3,267,238
of 23,202,641 outputs
Outputs from Frontiers in Microbiology
#3,092
of 25,460 outputs
Outputs of similar age
#20,176
of 182,300 outputs
Outputs of similar age from Frontiers in Microbiology
#16
of 123 outputs
Altmetric has tracked 23,202,641 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 25,460 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,300 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.